Trump Administration Permits Six Unapproved Peptides for Compounding by Small Pharmacies

The Trump administration has granted permission for small compounding pharmacies to produce six specific peptides, even though they have not yet received approval from the Food and Drug Administration (FDA), according to reports ¹²³⁴⁵⁶. This decision marks a notable shift in regulatory approach, as it employs 'enforcement discretion' for state-licensed pharmacies, federal facilities, and licensed physicians, making the policy temporary in nature ²⁵⁶.

The six peptides in question—BPC-157, TB-500, epitalon, MOTS-c, KPV, and semax—are currently not supported by published clinical trials proving their effectiveness in humans for any condition, despite showing promise in various research contexts ³⁶. This means that while these compounds may hold potential therapeutic benefits, their efficacy and safety remain unproven in human subjects.

In addition to the lack of clinical trial data, the FDA had previously determined that there was insufficient evidence to support the safety and effectiveness of these peptides, highlighting the cautious approach taken by the agency towards their use ⁶. However, the FDA's Pharmacy Compounding Advisory Committee (PCAC) demonstrated significant interest in these peptides, leading to a recent vote to add them to the FDA’s 503A list of bulk drug substances ⁶.

To ensure patient safety under this new policy, compounding pharmacies must adhere to strict requirements such as providing patient-specific prescriptions, using traceable ingredients, conducting quality testing, and maintaining safety reporting standards ³. Furthermore, in 2023, the FDA identified 19 peptides as unsafe for compounding, indicating a broader scrutiny of peptide-based treatments ³.

This policy change could potentially open up new avenues for patients seeking alternative therapies, although the absence of definitive clinical evidence means that caution is still warranted. As the pharmaceutical landscape continues to evolve, the impact of this decision on patient care and the broader market for compounded medications will be closely watched.

What we know

• - The Trump administration permits small compounding pharmacies to produce six specific peptides ¹²³⁴⁵⁶
• - These six peptides have not received approval from the FDA ¹²³⁵⁶
• - The six peptides include BPC-157, TB-500, epitalon, MOTS-c, KPV, and semax ³⁴⁵⁶
• - The policy is temporary and uses 'enforcement discretion' for state-licensed pharmacies, federal facilities, and licensed physicians ²⁵⁶
• - There are no published clinical trials proving these specific peptides' effectiveness in humans for any condition ³⁶
• - Patient-specific prescriptions, traceable ingredients, quality testing, and safety reporting are required ³
• - In 2023, the FDA deemed 19 peptides unsafe for compounding ³
• - The FDA's Pharmacy Compounding Advisory Committee showed significant interest in peptide use ⁶
• - The PCAC voted earlier this year to add these peptides to the FDA’s 503A list of bulk drug substances ⁶
• - FDA scientists previously concluded there was insufficient evidence to support the safety and effectiveness of these peptides ⁶